# Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis

> **NCT07726147** · PHASE1 · RECRUITING · sponsor: **Immunomic Therapeutics, Inc.** · enrollment: 45 (estimated)

## Conditions studied

- Allergen Immunotherapy

## Interventions

- **DRUG:** ITI-9001
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07726147
- **Lead sponsor:** Immunomic Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-20
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07726147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07726147, "Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07726147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*